

1 **Characterization of pyruvate dehydrogenase complex E1**

2 **alpha and beta subunits of *Mycoplasma synoviae***

3 Shijun Bao^{1*}, Xiaoqin Ding¹, Shengqing Yu², Chan Ding^{2*}

4 ¹College of Veterinary Medicine, Gansu Agricultural University, 1 Yingmencun, Lanzhou
5 730070, P.R. China.

6 ²Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 518
7 Ziyue Road, Minhang District, Shanghai 200241, P.R. China.

8 *Corresponding author:

9 Tel: +86-931-7631220; Fax: +86-931-7631220;

10 E-mail: bsjdy@126.com (S J Bao)

11 Tel: +86-21-34293441; fax: +86 21 34293441;

12 E-mail: shoveldeen@shvri.ac.cn (C. Ding).

13 **ABSTRACT** *Mycoplasma synoviae* (MS) is an important pathogen, causing enormous
14 economic losses to the poultry industry worldwide every year. Therefore, the studies on MS
15 will lay the foundation for diagnosis, prevention and treatment of MS infection. In this study,
16 primers designed based on the sequences of pyruvate dehydrogenase complex (PDC) E1 alpha
17 and beta subunit genes (*pdhA* and *pdhB*, respectively) of MS WVU1853 strain in GenBank
18 were used to amplify the *pdhA* and *pdhB* genes of MS WVU1853 strain through PCR. Then the
19 prokaryotic expression vectors pET-pdhA and pET-pdhB were constructed and were expressed
20 in *Escherichia coli* BL21(DE3) cells. Subsequently, the recombinant proteins rMSPDHA and
21 rMSPDHB were purified and anti-rMSPDHA and anti-rMSPDHB sera were prepared by
22 immunizing rabbits, respectively. Finally, the subcellular localization of PDHA and PDHB in
23 MS, binding activity of rMSPDHA and rMSPDHB to chicken plasminogen (Plg) and human
24 fibronectin (Fn), complement-dependent mycoplasmacidal assays, and adherence and
25 adherence inhibition assays were accomplished. The results showed that PDHA and PDHB

26 were distributed both on the surface membrane and within soluble cytosolic fractions of MS
27 cells. The rMSPDHA and rMSPDHB presented binding activity with chicken Plg and human
28 Fn. The rabbit anti-rMSPDHA and anti-rMSPDHB sera had distinct mycoplasmacidal efficacy
29 in the presence of guinea pig complement, and the adherence of MS to DF-1 cells pretreated
30 with Plg was effectively inhibited by treatment with anti-rMSPDHA or anti-rMSPDHB sera.
31 Hence, the study indicates that the surface-associated MSPDHA and MSPDHB are the
32 adhesion-related factors of MS that contributes to bind to Plg/Fn and adhesion to DF-1 cells.

33 **KEYWORDS** *Mycoplasma synoviae*; pyruvate decarboxylase; cloning; biological
34 characteristics

35 *Mycoplasma synoviae* (MS) is an important pathogen exerting significant economic impact
36 on poultry industry worldwide. MS infections can lead to a range of diseases, from subclinical
37 to severe ailments. In chickens, local infection of MS frequently causes subclinical disease of
38 the upper respiratory tract (Buim et al., 2009; Khiari et al., 2010; Landman, 2014; Wetzel et al.,
39 2010), while systemic infection of MS causes synovitis (Wetzel et al., 2010). Furthermore,
40 coinfection of MS with other respiratory pathogens, such as Newcastle disease virus, infectious
41 bursal disease virus, infectious bronchitis virus, *Escherichia coli*, and *Mycoplasma meleagridis*,
42 can induce airsacculitis, thereby further increasing economic losses (Giambrone et al., 1977;
43 Kleven, 1998; Limpavithayakul et al., 2016; May et al., 2007; Rhoades, 1977; Springer et al.,
44 1974; Vardaman et al., 1975). In addition to respiratory tract tropism strains and arthropathic
45 strains, oviduct tropism strains can induce eggshell apex abnormalities without any physical
46 abnormalities (Limpavithayakul et al., 2016). Therefore, research on MS can establish the
47 theoretical foundation for further development of vaccines, diagnostic reagents, and therapeutic
48 drugs against MS infections.

49 The pyruvate dehydrogenase complex (PDC) catalyzes the oxidative decarboxylation of
50 pyruvate to acetyl-CoA (Patel and Roche, 1990; Perham, 1991; Reed, 2001). Therefore, the

51 PDC occupies a key position in the oxidation of glucose by linking the glycolytic pathway to
52 the oxidative pathway of the tricarboxylic acid cycle. In prokaryotes and eukaryotes, the PDC
53 consists of three catalytic enzymes: pyruvate dehydrogenase (E1), dihydrolipoamide
54 acetyltransferase (E2), and dihydrolipoamide dehydrogenase (E3). The PDC E1 (EC 1.2.4.1) is a
55 thiamin diphosphate-dependent enzyme and catalyzes the oxidative decarboxylation of
56 pyruvate, which is the rate-limiting step in the overall activity of the PDC (Linn et al., 1969a;
57 Linn et al., 1969b; Patel et al., 2014). Previous studies have shown that the PDC E1 is a
58 heterotetramers ($\alpha_2\beta_2$) consisting of two alpha subunits and two beta subunits (Dahl et al., 1987;
59 Patel et al., 2014; Payton et al., 1977). In some *Mycoplasma* spp., the E1 beta subunit of PDC
60 acts as an immunogenic protein or plasminogen (Plg)/fibronectin (Fn) binding proteins (Dallo
61 et al., 2002; Sun et al., 2014; Thomas et al., 2013); however, there are still no reports on PDC
62 E1 of MS. Therefore, in the present study, the genes encoding the alpha and beta subunits of
63 PDC of MS were amplified and expressed in *E. coli*, respectively, and their biological
64 characteristics were investigated.

65 MATERIALS AND METHODS

66 **Enzymes and main reagents.** Restriction enzymes, T4 DNA ligase and PrimeSTAR® HS
67 DNA polymerase, were purchased from TaKaRa (Dalian, China). Complement sera (guinea pig
68 source) were bought from the Control Institute of Veterinary Bioproducts and Pharmaceuticals
69 (Beijing, China). The reagents used for cell culture were obtained from Gibco (Grand Island,
70 NY, USA). Other chemicals used in this study were of analytical grade and purchased from
71 Sigma-Aldrich (St. Louis, MO, USA) or Sangon Biotech (Shanghai, China).

72 **Bacterial strains, cell line, culture conditions, and plasmids.** *M. synoviae* WVU1853
73 strain was obtained from the Chinese Veterinary Culture Collection Center (CVCC, Beijing,
74 China) and cultured in Frey's medium (Frey et al., 1968) at 37°C in an atmosphere of 5% CO₂.
75 *E. coli* strains DH5 α and BL21(DE3) (TransGen, Beijing, China), which were used as

76 prokaryotic host for cloning and expression, respectively, were cultured in Luria-Bertani (LB)
77 broth or plated on LB agar supplemented with 50 µg/mL kanamycin at 37°C. DF-1 cells, a
78 continuous cell line of chicken embryo fibroblasts, were obtained from the American Type
79 Culture Collection (Manassas, VA, USA) and certified to be free of Mycoplasma
80 contamination, and were grown in Dulbecco's modified Eagle's medium (DMEM)
81 supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin
82 at 37°C in an atmosphere of 5% CO₂. The pET-28a(+) expression vector was obtained from
83 Novagen (Madison, WI, USA), and pET-InaZNEGFP was constructed in our previous study
84 (Bao et al., 2015).

85 **Cloning and expression of *pdhA* and *pdhB* genes of MS, and protein purification.** The
86 complete genome sequence of MS strain WVU1853 available in GenBank
87 (www.ncbi.nlm.nih.gov/genbank/) revealed that the open reading frame (ORF) of MS *pdhA*
88 gene containing eight TGA codons encodes tryptophan in *Mycoplasma* spp., but acts as stop
89 codons in *E. coli*. Therefore, primers *pdhA*-F1/*pdhA*-R1, *pdhA*-F2/*pdhA*-R2, *pdhA*-F3/*pdhA*-
90 R3, *pdhA*-F4/*pdhA*-R4, *pdhA*-F5/*pdhA*-R5, *pdhA*-F6/*pdhA*-R6, *pdhA*-F7/*pdhA*-R7, *pdhA*-
91 F8/*pdhA*-R8, and *pdhA*-F9/*pdhA*-R9 (Table 1) were designed for site-directed mutagenesis and
92 used in overlapping PCRs to amplify *pdhA*, while primers *pdhB*-F/*pdhB*-R (Table 1) were
93 employed to amplify *pdhB*. The full-length mutated *pdhA* and *pdhB* genes were amplified with
94 the introduction of *Bam*HI and *Xho*I restriction enzyme sites, respectively, and the recombinant
95 plasmids pET-*pdhA* and pET-*pdhB* were constructed and transformed into *E. coli* BL21(DE3)
96 cells, respectively. Recombinant rMSPDHA and rMSPDHB were then expressed through 1.0
97 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) induction and purified using Ni-NTA His-
98 Bind® Resin Kit (Novagen, San Diego, USA). The purified protein products were quantified by
99 using BCA Protein Assay Kit (Thermo Scientific-Pierce, Rockford, IL, USA) and analyzed by
100 10% SDS-PAGE with Coomassie blue staining.

101 **Preparation of anti-sera against rMSPDHA, rMSPDHB.** The anti-sera against
102 rMSPDHA, rMSPDHB, and MS whole cells were prepared by injecting female New Zealand
103 White rabbits with rMSPDHA, rMSPDHB, and inactivated whole-cell MS, respectively. Three
104 female rabbits were individually immunized four times by subcutaneous injection into the back
105 with purified recombinant proteins (800 µg) or inactivated whole-cell MS (10^{10} CFU), mixed
106 with Imject[®] Alum adjuvant (Thermo Scientific-Pierce, Waltham, MA, USA), at 2-week
107 intervals. Seven days after the fourth immunization, the rabbits were bled and the antibody
108 titers were measured by indirect ELISA (Bao et al., 2014). Aliquots of the serum samples were
109 the placed in 1.5-mL Eppendorf tubes and stored at -40°C for future use. All animal
110 experiments were approved by the Experimental Animal Ethic and Welfare Committee of
111 Gansu Agricultural University (China).

112 **Preparation of MS protein fractions.** Membrane and cytosolic proteins fractions from MS
113 were extracted using ReadyPrep[™] Protein Extraction Kit (Membrane I) (Bio-Rad, CA, USA)
114 according to the manufacturer's instructions. Subsequently, the membrane and cytosolic
115 proteins were dissolved in the same volume of protein solubilization buffer and equal volumes
116 of the solutions were respectively subjected to ELISA or Western blot. The MS whole cell
117 protein was prepared by using bacterial lysis buffer (Sangon, Shanghai, China) according to the
118 manufacturer's instructions. Protein quantitation was performed using BCA Protein Assay Kit
119 (Beyotime Institute of Biotechnology, Nan Tong, China).

120 **Analysis of PDHA and PDHB distribution in MS whole cells.** To confirm the distribution
121 of PDHA and PDHB in MS whole cells, equal volumes of membrane and cytosolic proteins
122 were subjected to western blot or ELISA. Western blot was performed as described previously
123 (Bao et al., 2014). In brief, the gels were transferred onto nitrocellulose (NC) membranes
124 (Whatman GmbH, Staufeu, Germany) and blocked with 5% skim milk for 3 h at room
125 temperature. Following three washes with PBST (3.2 mM Na_2HPO_4 , 0.5 mM KH_2PO_4 , 1.3 mM

126 KCl, 135 mM NaCl, 0.05% Tween 20, pH 7.4), the NC membranes were incubated with rabbit
127 anti-rMSPDHA or anti-rMSPDHB sera (dilution, 1:1000) at 4°C overnight. After washing
128 thrice, the NC membranes were incubated with goat anti-rabbit IgG conjugated to horseradish
129 peroxidase (HRP; Sigma-Aldrich; dilution, 1:8000) and the color reaction was examined using
130 ECL Kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Purified rMSPDHA and
131 rMSPDHB (1.5 µg) were used as positive control and bovine serum albumin (BSA, 1.5 µg) was
132 employed as negative control. The experiment was performed in triplicate and repeated three
133 times.

134 For ELISA, the 96-well plates were coated with equal volumes of membrane and cytosolic
135 proteins and incubated at 4°C overnight. After washing thrice with PBST, the wells were
136 blocked with 5% skim milk in PBST at 37°C for 3 h. The plates were then washed thrice and
137 rabbit anti-rMSPDHA sera or rabbit anti-rMSPDHB sera (100 µL/well; dilution, 1:1000) were
138 added to the wells and incubated for 2 h at 37°C. After washing, goat anti-rabbit IgG-HRP was
139 added to the wells (100 µL/well; Sigma-Aldrich; dilution, 1:5000) and the plates were
140 incubated at 37°C for 1 h. Finally, the color reaction was conducted by adding soluble
141 tetramethylbenzidine (TMB) substrate solution to the wells (100 µL/well; TIANGEN, Beijing,
142 China) and incubating the plates for 10 min at room temperature. The reaction was stopped with
143 2 M H₂SO₄ addition. The absorbance was measured at A₄₅₀ using a microplate reader (Bio-Tek
144 Instruments, Winooski, USA). Purified rMSPDHA and rMSPDHB (10 µg/well) were used as
145 positive control and BSA (10 µg/well) was employed as negative control. The experiment was
146 performed in triplicate and repeated three times.

147 **Complement-dependent mycoplasmacidal assays.** Complement-dependent
148 mycoplasmacidal activity of rabbit anti-rMSPDHA or anti-rMSPDHB sera was determined as
149 described previously (Bao et al., 2014). MS, grown to mid-logarithmic phase, was washed three
150 times with PBS by centrifugation at 5,000×g for 10 min at 4°C, and re-suspended in PBS at the

151 final concentration of 6×10^3 CFU/mL. The reaction system was established as follows: 160 μ L
152 of MS suspension and 60 μ L of rabbit anti-rMSPDHA or anti-rMSPDHB sera (1:5) were gently
153 mixed in 1.5-mL Eppendorf tube and incubated at 37°C for 30 min. Then, 30 μ L of diluted
154 complement (1:10) were added, mixed and incubated at 37°C for 1 h. The reaction mixture (50
155 μ L) was spread onto solid media in a 60-mm dish and incubated at 37°C in 5% CO₂ for 7 days
156 to count the colonies. Rabbit anti-MS sera and pre-immune rabbit sera were employed as
157 positive and negative control, respectively. In addition, controls for complement and PBS were
158 included. All sera (except for complement) used in the experiments were inactivated at 56°C for
159 30 min. Three independent experiments were performed in triplicate. The mycoplasmacidal
160 coefficient was calculated as follows: [(CFU of pre-immune serum treatment – CFU of
161 antiserum treatment)/(CFU of pre-immune serum treatment)] \times 100.

162 **Binding activity of rMSPDHA and rMSPDHB to Plg and Fn.** Western blot and ELISA
163 were used to determine the binding activity of rMSPDHA and rMSPDHB to chicken Plg (Cell
164 Sciences, MA, USA) and human Fn (Sigma-Aldrich) as described previously (Bao et al., 2014).
165 In brief, MS rMSPDHA or rMSPDHB was transferred onto nitrocellulose membranes,
166 incubated with chicken Plg or human Fn, and blots were developed with ECL Kit (Amersham
167 Pharmacia Biotech) according to the manufacturer's instructions.

168 ELISA was performed to verify the ability of the proteins to bind to Plg and Fn. In brief, the
169 wells of the ELISA plate were coated with chicken Plg or human Fn at a concentration of 50
170 ng/well and incubated at 4°C overnight. After washing, a range of concentrations of rMSPDHA
171 or rMSPDHB (0, 1, 5, 10, 15, 20, 25, or 30 μ g/mL in PBST) were added to the wells and
172 incubated for 2 h at 37°C. Then, the plates were incubated with rabbit anti-rMSPDHA or anti-
173 rMSPDHB sera (100 μ L/well; dilution, 1:1000) at 37°C for 1.5 h. After washing, goat anti-
174 rabbit IgG-HRP was added to the wells (100 μ L/well; Sigma-Aldrich; dilution, 1:5000), and the
175 plates were incubated at 37°C for 1 h. Subsequently, the color reaction was performed and the

176 absorbance was measured at A_{450} using a microplate reader (Bio-Tek Instruments). BSA were
177 used as negative control and all experiments were performed in triplicate and repeated thrice.

178 **Adherence and adherence inhibition test.** Adherence and adherence inhibition assays were
179 performed as previously described (Bao et al., 2015). *E. coli* surface display vectors pET-
180 InaZN-EGFP-pdhA/pET-InaZN-EGFP-pdhB were constructed, and *E. coli* BL21 (DE3) cells
181 harbouring InaZN-EGFP-pdhA or InaZN-EGFP-pdhB fusion protein were induced by IPTG,
182 centrifuged at 2500 g for 10 min and washed three times with DMEM. Then the DF-1 cells
183 grown to monolayers in 35-mm dishes were washed with DMEM and the pdhA-positive or
184 pdhB-positive *E. coli* cells were added to DF-1 cells at 100 multiplicity of infection (MOI) for
185 2h at 37°C in 5% CO₂. After washing with PBS to remove non-adherent *E. coli* cells, 1 ml of
186 4% paraformaldehyde was added to the monolayers, and the plate was then incubated at room
187 temperature for 10 min. After washing five times with PBS, the cell membranes were labelled
188 with 500 μ l of 10 μ mol l⁻¹ 1,1'-dioctadecyl-3,3',3'-tetramethylindocarbocyanine perchlorate
189 (Beyotime Institute of Biotechnology, Jiangsu, China) at room temperature for 10 min. After
190 washing five additional times with PBS, the cell nuclei were labelled with 500 μ l of 0.1 μ g ml⁻¹
191 of 4', 6-diamidino-2-phenylindole (Beyotime Institute of Biotechnology) at room temperature
192 for 10 min and then washed three times with PBS. Finally, the cells were mounted on slides and
193 observed by fluorescent microscopy to evaluate the adhesion properties of the cells. The
194 induced *E. coli* BL21(DE3) cells harboring InaZN-EGFP fusions acted as blank control, and all
195 the experiments were performed in triplicate and repeated thrice.

196 To further validate the adherence function of MSPDHA and MSPDHB,
197 adherence/adherence inhibition assay was conducted based on a bacteriological assay as
198 previously described (Chen et al., 2011; Song et al., 2012) with slight modifications. For the
199 adherence assay, DF-1 cells grown to a monolayer in a 35-mm dish were washed thrice with
200 PBS and incubated with Plg (10 μ g/mL) for 2 h at 37°C. The cells were then washed with

201 DMEM and the MS WVU1853 strain was added at a multiplicity of infection of 200 and
202 incubated for 2 h at 37°C and 5% CO₂. Non-adherent MS cells were removed by washing and
203 the infected cells were lysed with 0.25% trypsin (Gibco) and serial dilutions of the cell lysate
204 were then respectively plated onto solid medium and incubated for 96 h at 37°C and 5% CO₂.
205 The MS colonies were counted to determine the adherence frequency. For adherence inhibition
206 assay, the MS WVU1853 strain was incubated with rabbit anti-rMSPDHA/anti-rMSPDHB sera
207 or rabbit anti MS positive sera for 1 h at 37°C and then used to infect the DF-1 cells as
208 described earlier. The pre-immune rabbit sera acted as negative control and all experiments
209 were performed in triplicate and repeated thrice. The percent inhibition was calculated using the
210 following formula: (CFU of negative control – CFU of anti-serum treatment)/(CFU of negative
211 control)] × 100.

212 **Statistical analysis.** All data are expressed as the mean ± standard deviation of n
213 independent measurements. The statistical significance of the intergroup differences was
214 evaluated using Student's t-test. The SPSS software (SPSS, Chicago, IL, USA) was used to
215 calculate and analyze and the level of significance was set at P < 0.05 or P < 0.01.

216 RESULTS

217 **Expression of MS *pdhA* and *pdhB* genes, and purification of recombinant proteins.** The
218 full-length mutated *pdhA* and *pdhB* genes were amplified with the designed primers using
219 overlapping PCR, and the recombinant plasmid pET-*pdhA* and pET-*pdhB* were constructed.
220 Sequence analysis indicated that the *pdhA* and *pdhB* genes were 1125 and 993 bp in length,
221 respectively. The tryptophan codons (TGA) in the *pdhA* gene were successfully mutated to
222 TGG. Theoretically, *pdhA* gene encodes a 374-amino-acid protein with a relative molecular
223 weight of approximately 40.642 kDa, while *pdhB* gene encodes a 330-amino-acid protein with
224 a relative molecular weight of approximately 35.854 kDa.

225 The recombinant plasmids of pET-pdhA and pET-pdhB vectors were respectively
226 transformed into *E. coli* BL21(DE3) cells. The obtained recombinant proteins rMSPDHA and
227 rMSPDHB were expressed by 1.0 mM IPTG induction. The SDS-PAGE results showed that the
228 proportions of recombinant fusion proteins, rMSPDHA and rMSPDHB, were higher in the
229 supernatant than those in the sediment, and their apparent molecular weights were
230 approximately 44 and 39 kDa, respectively (Fig. 1). The purified recombinant proteins
231 presented a single band, respectively (Fig. 2).

232 **Preparation of rabbit anti-sera against rMSPDHA, rMSPDHB, and MS whole cells.**

233 One week after fourth immunization, the rabbits were bled and the reactivity and specificity of
234 the rabbit antisera were respectively tested by ELISA and western blot. The results showed that
235 the ELISA antibody titers of the anti-rMSPDHA, anti-rMSPDHB, or anti MS whole cells sera
236 were higher than 1:20,000. Western blot results demonstrated that both anti-rMSPDHA and
237 anti-rMSPDHB sera can specifically combine with MS bacterial protein and purified
238 rMSPDHA or rMSPDHB (Fig. 3).

239 **Localization of MSPDHA and MSPDHB.** MS PDHA and MS PDHB were detected in the
240 cell membrane fraction proteins (Fig. 4; Lanes 2, 6) and the cell soluble cytosolic fraction
241 proteins of MS (Fig. 4; Lanes 3, 7). Purified rMSPDHA, rMSPDHB (Fig. 4; Lanes 1, 5), and
242 BSA (Fig. 4; Lanes 4, 8) were employed as positive and negative controls, respectively. The
243 anti-rMSPDHA and anti-rMSPDHB sera could specifically combine with the protein of
244 approximately 41kDa and 36 kDa, respectively, while the band size of the binding recombinant
245 protein was about 44 kDa and 39 kDa, respectively. However, both anti-rMSPDHA and anti-
246 rMSPDHB sera had no binding band with BSA, suggesting that MS PDHA and PDHB were
247 present in both the membrane and soluble cytosolic protein fractions of MS cells. And the
248 results also indicated that the content of MS PDHA and PDHB in the membrane fractions was
249 higher than that in the cytosolic fractions. ELISA results (Fig. 5) also revealed that the content

250 of MS PDHA and PDHB in the membrane fractions was higher than that in the cytosolic
251 fractions ($P < 0.01$).

252 **Complement-dependent mycoplasmacidal assays.** As shown in Table 2, Complement-
253 dependent mycoplasmacidal assays revealed obvious difference in mycoplasmacidal activity
254 between anti-rMSPDHA/anti-rMSPDHB sera and pre-immune rabbit serum ($P < 0.01$). In
255 addition, the mycoplasmacidal activity of the rabbit anti-rMSPDHA was more effective than
256 that the anti-rMSPDHB sera, and the mycoplasmacidal rates were 65.6% and 29.89%,
257 respectively.

258 **Binding activity of rMSPDHA and rMSPDHB to Plg and Fn.** The ability of rMSPDHA
259 and rMSPDHB to bind to Plg and Fn was examined by western blot and ELISA. The western
260 blot analyses showed that both chicken Plg and human Fn bind to rMSPDHA and rMSPDHB,
261 as indicated by unique bands at 44 and 39 kDa, respectively (Fig. 6). ELISA revealed that both
262 rMSPDHA and rMSPDHB could bind to immobilized chicken Plg or human Fn in a dose-
263 dependent manner (Fig. 7). However, BSA, which was employed as the negative control,
264 showed no obvious binding effect with either chicken Plg or human Fn (Fig. 7).

265 **Adherence and adherence inhibition assays.** Adherence and adherence inhibition tests of
266 *E. coli* cells harboring InaZNEGFP-PDHA or InaZNEGFP-PDHB to DF-1 cells showed that
267 the PDHA-and PDHB-positive *E. coli* transformants were able to specifically attach to DF-1
268 cells, which can be inhibited by rabbit anti-rMSPDHA/anti-rMSPDHB sera (Fig. 8). However,
269 the induced *E. coli* transformants harboring pET-InaZNEGFP were unable to attach to DF-1
270 cells (Fig. 8), indicating that both MS PDHA and MS PDHB are adhesion-related factors.

271 To further validate the effect of MSPDHA and MSPDHB on the adherence of MS to DF-1
272 cells, the adherence and adherence inhibition values were calculated. As table 3 shows that the
273 rabbit anti-rMSPDHA/anti-rMSPDHB sera had significant inhibitory effect on the adherence of

274 MS to DF-1 cells ($P < 0.01$). There was apparent difference in adherence inhibition rate between
275 the anti-rMSPDHA/anti-rMSPDHB sera and pre-immune rabbit serum ($P < 0.01$), and the anti-
276 rMSPDHA sera were more effective than the anti-rMSPDHB sera at inhibiting adherence ($P <$
277 0.01). Thus, these results demonstrated that MSPDHA and MSPDHB are adhesion-related
278 proteins.

279 **DISCUSSION**

280 MS is a major pathogen of avian, which is widely distributed around the world and leads to
281 serious economic losses in the world every year. Therefore, the MS association studies will lay
282 the foundation for diagnosis, prevention and treatment of MS infection. Prior to this study,
283 some major immunogenic proteins of MS isolates were identified, including PDC E1 alpha and
284 beta subunit, elongation factor Tu (EF-Tu), enolase, etc. (Bao et al., 2017; Bercic et al., 2008).
285 As a component of the PDC, the PDC E1 not only plays the important role in energy
286 metabolism, but performs additional biological functions, including immunogenicity, adhesion
287 and invasion of pathogenic microorganisms to host cells (Sun et al., 2014; Vastano et al., 2014).
288 Currently, PDC E1 from various plants and yeasts have been separated and identified, but there
289 have been only a few reports on PDC E1 from bacteria. Bacteria-derived PDC E1 catalyzes
290 ethanol production through Entner-Doudoroff pathway, rather than pyruvate generation through
291 glycolysis. Therefore, studies on PDC E1, especially those on PDC E1 from thermophilic
292 bacteria (Van Zyl et al., 2014), have been mainly focused on its biocatalysis, because it is safe,
293 pollution-free, and highly efficient (Taylor et al., 2009). Nevertheless, no study on the PDC E1
294 of MS has been reported up to present.

295 In this study, the pdhA and pdhB of MS were amplified, optimized and expressed in a
296 prokaryotic system, respectively. And both recombinant proteins could express in BL21(DE3)
297 in soluble form. Then anti-rMSPDHA/anti-rMSPDHB sera were prepared. These laid the
298 foundation for study on other biological functions of MS PDHA and PDHB. Subsequently, the

299 immunogenic proteins with good immunogenicity of MSPDHA and MSPDHB were confirmed
300 by indirect ELISA and western blot, consistent with previous research(Bao et al., 2017). The
301 similar finding has been made in *M. bovis* (Sun et al., 2014).

302 That the MSPDHA and MSPDHB are present in both the soluble cytosolic fraction and the
303 membrane fraction of MS has been demonstrated, and with higher distribution in the cell
304 membrane fraction than in the cytosolic fraction (Fig.4 and 5). This analysis demonstrates that
305 MSPDHA and MSPDHB are respectively the membrane-associated protein in MS, suggesting
306 that MSPDHA and MSPDHB might possess various biological functions besides the catalytic
307 activity catalyst, such as some membrane-associated proteins have been found in previous
308 studies (Bao et al., 2014; Gao et al., 2018; Salzillo et al., 2017). We suggest that the distribution
309 in the cell membrane fraction of MSPDHA and MSPDHB is consistent with the etiology of
310 adherence to host cells.

311 We have also demonstrated that rabbit anti-rMSPDHA/anti-rMSPDHB sera displayed a
312 significant complement-dependent mycoplasmacidal effect, and the mycoplasmacidal activity
313 of the rabbit anti-rMSPDHA was more effective than that the anti-rMSPDHB sera (Table 2), the
314 similar biological function of other proteins of MS has been previously reported(Bao et al.,
315 2014; Gao et al., 2018). This suggested that MSPDHA and MSPDHB should play an important
316 role in host immunity against MS infection.

317 The binding activity of MSPDHA and MSPDHB to chicken Plg and human Fn has been
318 confirmed in the present study. The western blot analyses demonstrate the binding specificity of
319 MSPDHA and MSPDHB to chicken Plg and human Fn (Fig. 6), and the ELISA revealed that
320 the binding of MSPDHA and MSPDHB to chicken Plg or human Fn in a dose-dependent
321 manner. The PDHB acts as fibronectin and plasminogen-binding protein has already been
322 demonstrated in other microorganisms (Dallo et al., 2002; Salzillo et al., 2017; Thomas et al.,
323 2013), but the binding activity of MSPDHA to chicken Plg and human Fn was first
324 confirmation in this study. Those suggested that MSPDHA and MSPDHB are the major Plg/Fn-

325 binding protein in MS; this could be of great importance for Mycoplasma establishment in the
326 host. Therefore, we speculate that a-enolase is involved in MS adhesion to DF-1 cells.

327 To confirm the adhesion activity of MSPDHA and MSPDHB to host cells, both E. coli cells
328 harboring InaZNEGFP-pdhA/InaZNEGFP-pdhB and MS were subjected to the adherence and
329 inhibition assay in vitro. In this work the adhesion ability of MSPDHA and MSPDHB to DF-1
330 cells has been demonstrated, and this adhesion was effectively inhibited by the addition of anti-
331 rMSPDHA/anti-rMSPDHB sera, suggesting that MSPDHA and MSPDHB are adhesion-related
332 proteins on MS cell membrane surface. Based on this, we speculate that MSPDHA and
333 MSPDHB may participate in adhesion, colonization, and invasion of MS to host cells, and may
334 be involved in various clinical and pathologic sequelae of MS infection, such as synovitis,
335 tenosynovitis and arthritis.

336 CONCLUSIONS

337 The studies show that the MSPDHA and MSPDHB are surface-exposed proteins with
338 excellent immunogenicity, and that rabbit anti-rMSPDHA/anti-rMSPDHB sera had a significant
339 complement-dependent mycoplasmacidal effect. Furthermore, the findings also demonstrated
340 the binding ability of MSPDHA and MSPDHB to chicken Plg and human Fn, as well as the
341 adherence to DF-1 cells. These results suggested that MSPDHA and MSPDHB play important
342 role in MS metabolism, infection, and immunity, providing the basis for further research on the
343 functions of MSPDHA and MSPDHB.

344 FUNDING INFORMATION

345 This work was supported by the National Natural Science Foundation of China (31360620)
346 and Natural Science Foundation of Gansu Province, China (1308RJZA235).

347 CONFLICT OF INTEREST

348 The authors declare that they have no competing interests.

349 ACKNOWLEDGMENTS

350 We are thankful to the Laboratory of Veterinary Lemology, Gansu Agricultural University,
351 China, and the Key Open Laboratory of Shanghai Veterinary Research Institute, CAAS, for
352 providing key laboratory equipment.

353 REFERENCES

- 354 Bao, S., Guo, X., Yu, S., Ding, J., Tan, L., Zhang, F., Sun, Y., Qiu, X., Chen, G., Ding, C., 2014. Mycoplasma
355 synoviae enolase is a plasminogen/fibronectin binding protein. BMC Vet Res 10, 223.
- 356 Bao, S., J., Ding, X.Q., Xing, X.Y., Fu, X.P., Xue, H.W., Wen, F.Q., 2017. Preliminary analysis of immune-related
357 membrane proteins from mycoplasma synoviae WVU1853 strain. Acta Veterinary et Zootechnica Sinic 48,
358 316-323.
- 359 Bao, S., Yu, S., Guo, X., Zhang, F., Sun, Y., Tan, L., Duan, Y., Lu, F., Qiu, X., Ding, C., 2015. Construction of a
360 cell-surface display system based on the N-terminal domain of ice nucleation protein and its application in
361 identification of mycoplasma adhesion proteins. Journal of applied microbiology 119, 236-244.
- 362 Bercic, R.L., Slavec, B., Lavric, M., Narat, M., Bidovec, A., Dovc, P., Bencina, D., 2008. Identification of major
363 immunogenic proteins of Mycoplasma synoviae isolates. Vet Microbiol 127, 147-154.
- 364 Buim, M.R., Mettifogo, E., Timenetsky, J., Kleven, S., Ferreira, A.J.P., 2009. Epidemiological survey on
365 Mycoplasma gallisepticum and M.synoviae by multiplex PCR in commercial poultry. Pesq. Vet. Bras 29, 552-
366 556.
- 367 Chen, H., Yu, S., Shen, X., Chen, D., Qiu, X., Song, C., Ding, C., 2011. The Mycoplasma gallisepticum alpha-
368 enolase is cell surface-exposed and mediates adherence by binding to chicken plasminogen. Microbial
369 pathogenesis 51, 285-290.
- 370 Dahl, H.H., Hunt, S.M., Hutchison, W.M., Brown, G.K., 1987. The human pyruvate dehydrogenase complex.
371 Isolation of cDNA clones for the E1 alpha subunit, sequence analysis, and characterization of the mRNA. The
372 Journal of biological chemistry 262, 7398-7403.
- 373 Dallo, S.F., Kannan, T.R., Blaylock, M.W., Baseman, J.B., 2002. Elongation factor Tu and E1 beta subunit of
374 pyruvate dehydrogenase complex act as fibronectin binding proteins in Mycoplasma pneumoniae. Mol
375 Microbiol 46, 1041-1051.
- 376 Frey, M.L., Hanson, R.P., Anderson, D.P., 1968. A medium for the isolation of avian mycoplasmas. American
377 journal of veterinary research 29, 2163-2171.
- 378 Gao, X., Bao, S., Xing, X., Fu, X., Zhang, Y., Xue, H., Wen, F., Wei, Y., 2018. Fructose-1,6-bisphosphate aldolase
379 of Mycoplasma bovis is a plasminogen-binding adhesin. Microbial pathogenesis 124, 230-237.
- 380 Giambrone, J.J., Eidson, C.S., Kleven, S.H., 1977. Effect of infectious bursal disease on the response of chickens
381 to Mycoplasma synoviae, Newcastle disease virus, and infectious bronchitis virus. Am J Vet Res 38, 251-253.
- 382 Khiari, A.B., Gueriri, I., Mohammed, R.B., Mardassi, B.B., 2010. Characterization of a variant vlhA gene of
383 Mycoplasma synoviae, strain WVU 1853, with a highly divergent haemagglutinin region. BMC Microbiol 10,

- 384 6.
- 385 Kleven, S.H., 1998. Mycoplasmas in the etiology of multifactorial respiratory disease. *Poultry science* 77, 1146-
- 386 1149.
- 387 Landman, W.J., 2014. Is *Mycoplasma synoviae* outrunning *Mycoplasma gallisepticum*? A viewpoint from the
- 388 Netherlands. *Avian Pathol* 43, 2-8.
- 389 Limpavithayakul, K., Sasipreeyajan, J., Pakpinyo, S., 2016. Characterization of Thai *Mycoplasma synoviae*
- 390 Isolates by Sequence Analysis of Partial *vlhA* Gene. *Avian Dis* 60, 810-816.
- 391 Linn, T.C., Pettit, F.H., Hucho, F., Reed, L.J., 1969a. Alpha-keto acid dehydrogenase complexes. XI. Comparative
- 392 studies of regulatory properties of the pyruvate dehydrogenase complexes from kidney, heart, and liver
- 393 mitochondria. *Proceedings of the National Academy of Sciences of the United States of America* 64, 227-234.
- 394 Linn, T.C., Pettit, F.H., Reed, L.J., 1969b. Alpha-keto acid dehydrogenase complexes. X. Regulation of the activity
- 395 of the pyruvate dehydrogenase complex from beef kidney mitochondria by phosphorylation and
- 396 dephosphorylation. *Proceedings of the National Academy of Sciences of the United States of America* 62, 234-
- 397 241.
- 398 May, M., Kleven, S.H., Brown, D.R., 2007. Sialidase activity in *Mycoplasma synoviae*. *Avian Dis* 51, 829-833.
- 399 Patel, M.S., Nemeria, N.S., Furey, W., Jordan, F., 2014. The pyruvate dehydrogenase complexes: structure-based
- 400 function and regulation. *J Biol Chem* 289, 16615-16623.
- 401 Patel, M.S., Roche, T.E., 1990. Molecular biology and biochemistry of pyruvate dehydrogenase complexes.
- 402 *FASEB J* 4, 3224-3233.
- 403 Payton, M.A., McCullough, W., Roberts, C.F., Guest, J.R., 1977. Two unlinked genes for the pyruvate
- 404 dehydrogenase complex in *Aspergillus nidulans*. *J Bacteriol* 129, 1222-1226.
- 405 Perham, R.N., 1991. Domains, motifs, and linkers in 2-oxo acid dehydrogenase multienzyme complexes: a
- 406 paradigm in the design of a multifunctional protein. *Biochemistry* 30, 8501-8512.
- 407 Reed, L.J., 2001. A trail of research from lipoic acid to alpha-keto acid dehydrogenase complexes. *J Biol Chem*
- 408 276, 38329-38336.
- 409 Rhoades, K.R., 1977. Turkey sinusitis: synergism between *Mycoplasma synoviae* and *Mycoplasma meleagridis*.
- 410 *Avian Dis* 21, 670-674.
- 411 Salzillo, M., Vastano, V., Capri, U., Muscariello, L., Marasco, R., 2017. Pyruvate dehydrogenase subunit beta of
- 412 *Lactobacillus plantarum* is a collagen adhesin involved in biofilm formation. *J Basic Microbiol* 57, 353-357.
- 413 Song, Z., Li, Y., Liu, Y., Xin, J., Zou, X., Sun, W., 2012. alpha-Enolase, an adhesion-related factor of *Mycoplasma*
- 414 *bovis*. *PloS one* 7, e38836.
- 415 Springer, W.T., Luskus, C., Pourciau, S.S., 1974. Infectious bronchitis and mixed infections of *Mycoplasma*
- 416 *synoviae* and *Escherichia coli* in gnotobiotic chickens. I. Synergistic role in the airsacculitis syndrome. *Infect*
- 417 *Immun* 10, 578-589.
- 418 Sun, Z., Fu, P., Wei, K., Zhang, H., Zhang, Y., Xu, J., Jiang, F., Liu, X., Xu, W., Wu, W., 2014. Identification of
- 419 novel immunogenic proteins from *Mycoplasma bovis* and establishment of an indirect ELISA based on
- 420 recombinant E1 beta subunit of the pyruvate dehydrogenase complex. *PLoS One* 9, e88328.
- 421 Taylor, M.P., Eley, K.L., Martin, S., Tuffin, M.I., Burton, S.G., Cowan, D.A., 2009. Thermophilic ethanologensis:

- 422 future prospects for second-generation bioethanol production. *Trends Biotechnol* 27, 398-405.
- 423 Thomas, C., Jacobs, E., Dumke, R., 2013. Characterization of pyruvate dehydrogenase subunit B and enolase as
424 plasminogen-binding proteins in *Mycoplasma pneumoniae*. *Microbiology* 159, 352-365.
- 425 Van Zyl, L.J., Taylor, M.P., Eley, K., Tuffin, M., Cowan, D.A., 2014. Engineering pyruvate decarboxylase-
426 mediated ethanol production in the thermophilic host *Geobacillus thermoglucosidasius*. *Appl Microbiol*
427 *Biotechnol* 98, 1247-1259.
- 428 Vardaman, T.H., Deaton, J.W., Feece, F.N., 1975. Serological responses of broiler-type chickens, with and without
429 Newcastle disease and infectious Bronchitis vaccine, to experimental infection with *Mycoplasma synoviae* by
430 foot pad, air sac and aerosol. *Poult Sci* 54, 737-741.
- 431 Vastano, V., Salzillo, M., Siciliano, R.A., Muscariello, L., Sacco, M., Marasco, R., 2014. The E1 beta-subunit of
432 pyruvate dehydrogenase is surface-expressed in *Lactobacillus plantarum* and binds fibronectin. *Microbiol Res*
433 169, 121-127.
- 434 Wetzel, A.N., Lefevre, K.M., Raviv, Z., 2010. Revised *Mycoplasma synoviae* vlhA PCRs. *Avian Dis* 54, 1292-
435 1297.
- 436

1 **Figure legends**

2 **Fig. 1** Analysis of the expression of recombinant proteins using SDS-PAGE followed by
3 Coomassie blue staining. M: Pre-stained protein molecular weight marker (SM1811,
4 Fermentas); Lane 1: Precipitation of lysate of *E. coli* BL21(DE3) cells transformed by
5 pET-pdhA; Lane 2: Supernatant of lysate of *E. coli* BL21(DE3) cells transformed by pET-pdhA;
6 Lane 3: Total cellular proteins of *E. coli* BL21 (DE3) cells transformed by pET-28a (+); Lane 4:
7 Total cellular proteins of *E. coli* BL21 (DE3) cells transformed by pET-pdhA; Lane 5:
8 Precipitation of lysate of *E. coli* BL21(DE3) cells transformed by pET-pdhB; Lane 6:
9 Supernatant of lysate of *E. coli* BL21(DE3) cells transformed by pET-pdhB.

10

11 **Fig.2** Analysis of purified recombinant proteins using SDS-PAGE followed by Coomassie blue
12 staining. M: Pre-stained protein molecular weight marker (SM1811, Fermentas); Lane 1:
13 Purified rMSPDHA; Lane 2: Purified rMSPDHB.

14

15 **Fig. 3** Western blot analysis of rabbit anti-rMSPDHA and anti-rMSPDHB sera. A1: Western
16 blot analysis of rabbit anti-rMSPDHA serum; A2: Negative serum from rabbit; Lane 1: Purified
17 rMSPDHA protein; Lane 2: Total proteins of MS WVU1853 strain; Lane 3: BSA control. B1:
18 Western blot analysis of rabbit anti-rMSPDHB serum; B2: Negative serum from rabbit; Lane 1:
19 Purified rMSPDHB protein; Lane 2: Total proteins of MS WVU1853 strain; Lane 3: BSA
20 control

21

22 **Fig. 4** Western blot analysis of localization of MSPDHA and MSPDHB. Panel A: Western blot
23 analysis using anti-rMSPDHA; Panel B: Western blot analysis using anti-rMSPDHB; Lanes 1,
24 5: Purified rMSPDHA and rMSPDHB, used as positive control; Lanes 2, 6: Membrane proteins
25 of MS; Lanes 3, 7: Cytosolic proteins of MS; Lanes 4, 8: BSA was used as negative control.

26

27 **Fig. 5** ELISA of MSPDHA and MSPDHB localization. Panel A: ELISA of PDHA distribution
28 in the membrane and soluble cytosolic protein fractions of MS cells using anti-rMSPDHA;
29 Panel B: ELISA of PDHB distribution in the membrane and soluble cytosolic protein fractions
30 of MS cells using anti-rMSPDHB.

31

32 **Fig.6** Western blot analysis of the binding ability of rMSPDHA and rMSPDHB to chicken Plg
33 or human Fn. Panel A: Western blot analysis using anti-rMSPDHA; Panel B: Western blot
34 analysis using anti-rMSPDHB; Lane 1: Chicken Plg; Lane 3: Human Fn; Lanes 2, 4: BSA.

35

36 **Fig.7** ELISA of MSPDHA and MSPDHB binding to chicken Plg or human Fn. (A) ELISA of
37 the binding ability of rMSPDHA to chicken Plg. (B) ELISA of the binding ability of rMSPDHB
38 to chicken Plg. (C) ELISA of the binding ability of rMSPDHA to human Fn. (D) ELISA of the
39 binding ability of rMSPDHB to human Fn.

40

41 **Fig.8** Adherence and adherence inhibition assays. IA: Adherence of *E. coli* cells harboring
42 InaZNEGFP-PDHA to DF-1 cells; IB: Adherence of *E. coli* cells harboring InaZNEGFP to
43 DF-1 cells; IC: Adherence inhibition by rabbit anti-rMSPDHA sera. IIA: Adherence of *E. coli*
44 cells harboring InaZNEGFP-PDHB to DF-1 cells; IIB: Adherence of *E. coli* cells harboring
45 InaZNEGFP to DF-1 cells; IIC: Adherence inhibition by rabbit anti-rMSPDHB sera.

46

kDa

M

1

2

3

4

5

6

170

130

95


72

55

43


36



26






←44kDa

←39kDa














A

The distribute of PDHA in differnent fractions of MS

B

The distribute of PDHB in differnent fractions of MS



A**B****C****D**




Table 1 Primers used in this study

| The name of the primer | Primer sequences (5'→3') | Localization (nt) |
|------------------------|---|-------------------|
| pdhA-F1 | GGAGGATCC ^a TCAACAAAATACAA | 1–162 |
| pdhA-R1 | GATAAAACCATC ^b CATTTGTAACCT | |
| pdhA-F2 | AGGTTACAAATGG ^b ATGGTTTTATC | 162–300 |
| pdhA-R2 | TGGTAGGAAC ^b CAATCTTTTTCTTGT | |
| pdhA-F3 | ACAAGAAAAAAGATTGG ^b TTCCCTACCA | 300–375 |
| pdhA-R3 | TCGTTACCGTC ^b CAATATAACATTTG | |
| pdhA-F4 | CAAATGTTATATTGG ^b AACGGTAACGA | 375–588 |
| pdhA-R4 | CAAAATACAGCAGGC ^b CAGCTTCTAACT | |
| pdhA-F5 | AGTTAGAAGCTGG ^b CCTGCTGATTTTG | 588–621 |
| pdhA-R5 | TTGAAATTGCC ^b CATTGGTTGTTA | |
| pdhA-F6 | TAACAACCAATGG ^b GCAATTTCAA | 621–807 |
| pdhA-R6 | GCCTTGCTC ^b CAAGTTACAAATCC | |
| pdhA-F7 | GGAATTTGTAACCTGG ^b AGACAAGGC | 807–885 |
| pdhA-R7 | TGCATTGGTTCC ^b CATACTTCTTG | |
| pdhA-F8 | CAAGAAGTATGG ^b GAACCAATGCA | 885–960 |
| pdhA-R8 | AGAGAATCAGCC ^b CAGATTTTTTCA | |
| pdhA-F9 | TGAAAAAATCTGG ^b GCTGATTCTCT | 960–1125 |
| pdhA-R9 | TTACTCGAG ^a ATTATTTCCCTCCG | |
| pdhB-F | GGAGGATCC ^a ATGTCTGATAAAAAATAACAG | 1–993 |
| pdhB-R | TTACTCGAG ^a CTAAAATTTAAATGAAGTAACT | |

^aRestriction sites of GGATCC and CTCGAG for endonuclease *Bam*HI and *Xho*I are shown in underlined italics.

^bNucleotide substitutions are shown in boldface.

^cLocalization was based on the nucleotide sequence of MS 53 *pdhA* (Gene ID:3564398) and *pdhB* (Gene ID:3564399) genes.

Table 2 Mycoplasmacidal activity of rabbit anti-rMSPDHA/anti-rMSPDHB sera

| Sera Type | Mean CFU of MS (10^4) | Mycoplasmacidal coefficient (%) |
|--------------------------|---------------------------|---------------------------------|
| MS positive sera | 10 | 96.5* |
| Rabbit anti-rMSPDHA sera | 100 | 65.6* |
| Rabbit anti-rMSPDHB sera | 204 | 29.89* |
| pre-immune rabbit sera | 291 | — |

*P < 0.01, compared with the corresponding group using pre-immune rabbit serum.

Table 3 CFU values of different treatment groups

| Serum | Mean CFU of MS(10^4) | Adhesion inhibition rate(%) |
|------------------------------|--------------------------|-----------------------------|
| Rabbit anti MS positive sera | 60 | 93.33* |
| Rabbit anti-rMSPDHA sera | 132 | 85.33* |
| Rabbit anti-rMSPDHB sera | 170 | 81.11* |
| pre-immune rabbit sera | 900 | — |

*P < 0.01, compared with the corresponding group using pre-immune rabbit serum(negative control).